<ul><li>Colorectal cancer (CRC) is a significant challenge in oncology and a leading cause of cancer-related deaths globally.</li><li>Recent research published in BMC Cancer highlights targeting the biomarker INF2 for CRC treatment.</li><li>INF2 is overexpressed in colorectal tumors and correlates with disease progression, making it a prognostic biomarker.</li><li>In vitro studies show that inhibiting INF2 reduces tumor cell proliferation and migration.</li><li>Researchers identified DiosMetin 7-O-β-D-Glucuronide as a compound that selectively inhibits INF2.</li><li>DiosMetin 7-O-β-D-Glucuronide impairs actin polymerization in CRC cells with minimal effects on normal cells.</li><li>Immunohistochemical analyses support INF2 as a marker of disease severity in CRC patients.</li><li>Targeting INF2 with DiosMetin represents a precise and novel approach to CRC therapy.</li><li>The study showcases the potential of natural compounds and computational biology in oncology.</li><li>INF2 inhibition offers a targeted therapeutic strategy with reduced side effects compared to conventional chemotherapies.</li></ul>

DiosMetin Targets INF2: New Colorectal Therapy

Discover more